Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Lab has informed that the Board of Directors approved the Audited Standalone and Consolidated Financial Results of the Company for the Year ended March 31, 2024 and Limited Reviewed Financial Results of the Company for the Quarter ended March 31, 2024 at their meeting held on April 25, 2024, which are enclosed along with the Audit Reports (including Limited Review Reports) issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India: www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 02.00 pm and concluded at 02.45 pm.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1841.50 |
Dr. Reddys Lab | 1355.15 |
Cipla | 1489.20 |
Lupin | 2181.60 |
Zydus Lifesciences | 959.55 |
View more.. |